2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Gilead Sciences company profile · HIV, oncology & liver disease franchises · history · financial snapshot · S&P 500 rank #58 · 吉利德科學公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | GILD (NASDAQ) |
| Company | Gilead Sciences, Inc. |
| GICS sector / industry | Health Care (XLV) / Biotechnology |
| S&P 500 rank (by weight) | #58 · 0.29% (Oct 29, 2026) |
| Sector rank (by market cap) | #8 in Health Care (Oct 29, 2026) |
| Headquarters | Foster City, California |
| Founded | June 22, 1987, Foster City, California |
| CEO | Daniel O’Day (since March 2019) |
| Employees | ≈17,000 (Dec 31, 2025, FY2025 10-K) |
| Market cap | $197.40B (Oct 28, 2026 close) |
| SEC filings | EDGAR — CIK 0000882095 |
WHAT IT DOES
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. It reports one operating segment; almost all revenue is product sales, led by antiviral franchises built over three decades — HIV first, viral hepatitis second, and a younger oncology business assembled by acquisition.
HIV is the engine: $20.75B of FY2025 revenue (70.5% of the total), led by Biktarvy at $14.33B — a once-daily single-tablet regimen that is the most prescribed HIV treatment in the United States — with Descovy ($2.76B) carrying the prevention (PrEP) side. Liver disease adds $3.22B (Epclusa and Vemlidy in viral hepatitis, Livdelzi in primary biliary cholangitis). Oncology contributes $3.24B: the antibody–drug conjugate Trodelvy ($1.40B) and Kite Pharma’s CAR T cell therapies Yescarta and Tecartus ($1.84B combined). Veklury (remdesivir) has faded to $0.91B as COVID-19 hospitalizations fall.
The model is chronic, guideline-embedded therapy at very high gross margin (78.8% in FY2025) converted into research funding — $5.80B of R&D and more than 50 clinical-stage programs — plus disciplined buying of external science (Pharmasset in 2011, Kite in 2017, Immunomedics in 2020, CymaBay in 2024). The current growth story is lenacapavir, the first-in-class capsid inhibitor dosed twice a year: Sunlenca in treatment and Yeztugo, approved in June 2025 as the first twice-yearly PrEP option.
BUSINESS SEGMENTS — FY2025 REVENUE BY PRODUCT AREA
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| HIV | $20.75B | 70.5% | +6% |
| Oncology | $3.24B | 11.0% | −2% |
| Liver Disease | $3.22B | 10.9% | +6% |
| Veklury (COVID-19) | $0.91B | 3.1% | −49% |
| Other products | $0.80B | 2.7% | −10% |
| Royalty, contract & other | $0.53B | 1.8% | +266% |
| Total revenues | $29.44B | 100% | +2% |
HISTORY
| Year | Milestone |
|---|---|
| 1987 | Founded in Foster City, California, by physician Michael L. Riordan |
| 1992 | IPO on NASDAQ |
| 2001 | Viread (tenofovir) approval starts the HIV franchise build-out |
| 2006 | Atripla — the first once-daily single-tablet HIV regimen (with Bristol-Myers Squibb) |
| 2011 | Announces the $11B acquisition of Pharmasset, owner of sofosbuvir |
| 2013 | Sovaldi launches; the curative hepatitis C era begins |
| 2014 | Harvoni — first all-oral, interferon-free HCV cure regimen |
| 2016 | Epclusa — first pan-genotypic HCV regimen |
| 2017 | Acquires Kite Pharma for $11.9B; Yescarta becomes a first-in-class CAR T cell therapy |
| 2018 | Biktarvy launches and grows into the world’s leading HIV regimen |
| 2019 | Daniel O’Day becomes chairman and CEO |
| 2020 | Veklury (remdesivir) is the first FDA-approved COVID-19 treatment; acquires Immunomedics for $21B (Trodelvy) |
| 2022 | Sunlenca (lenacapavir) approved — first twice-yearly HIV treatment option |
| 2024 | Acquires CymaBay Therapeutics, adding Livdelzi (primary biliary cholangitis) |
| 2025 | Yeztugo (lenacapavir) approved as twice-yearly HIV prevention (PrEP) |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total revenues | $29.44B (+2% YoY) |
| Product sales | $28.92B · 98.2% of total revenue |
| Gross profit | $23.21B · 78.8% margin |
| Operating income | $10.02B · 34.0% margin |
| Net income | $8.51B · 28.9% margin |
| Diluted EPS | $6.78 (vs $0.38 in FY2024 — see note) |
| Operating cash flow | $10.02B |
| Cash & marketable debt securities | $10.61B (Dec 31, 2025) |
| Research & development | $5.80B · 19.7% of revenue |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Gilead is the S&P 500’s #58 constituent at a 0.29% weight and #8 within Health Care — a 1% move in GILD moves the index by only about 0.3 basis points on its own, but the stock is the market’s purest large-cap read on HIV economics and a top-ten health care name, so its results steer biotech sentiment well beyond its weight (XLV and XBI read-through).
For index and 0DTE traders specifically: Gilead reports in the February / May / August / November biotech windows, lenacapavir regulatory and clinical headlines land without warning, and HIV policy news out of Washington can gap the whole antiviral complex — GILD is usually the first name through which that flow expresses itself.
SOURCES & METHODOLOGY
| Financials, product sales, employees | Gilead Sciences FY2025 Form 10-K (filed Feb 24, 2026; fiscal year ended Dec 31, 2025) |
| Index weight & rank | Slickcharts S&P 500 weights, crawled Oct 29, 2026 (frozen benchmark) |
| Market cap & sector rank | StockAnalysis S&P 500 list, Oct 28, 2026 close snapshot; GICS sector per List of S&P 500 companies (Wikipedia) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | GILD(NASDAQ) |
| 公司 | Gilead Sciences, Inc.(吉利德科學) |
| GICS 板塊/行業 | 醫療健康(XLV)/生物科技 |
| 標普500排名(按權重) | #58 · 0.29%(2026年10月29日) |
| 板塊內排名(按市值) | 醫療健康 #8(2026年10月29日) |
| 總部 | 加州福斯特城 |
| 成立 | 1987年6月22日,加州福斯特城 |
| 執行長 | Daniel O’Day(2019年3月起) |
| 員工 | 約17,000人(2025年12月31日,FY2025 10-K) |
| 市值 | $197.40B(2026年10月28日收盤) |
| SEC 申報 | EDGAR — CIK 0000882095 |
業務概覽
吉利德科學是一家生物製藥公司,專注於未滿足醫療需求領域的創新藥物發現、開發與商業化。公司只有一個經營板塊,收入幾乎全部來自產品銷售,由三十年累積的抗病毒產品線主導——HIV 第一、病毒性肝炎第二,加上以收購組建的較年輕腫瘤業務。
HIV 是引擎:FY2025 收入 $20.75B(佔總收入 70.5%),由 Biktarvy 的 $14.33B 領跑——這款每日一次的單片方案是美國處方量最高的 HIV 治療;Descovy($2.76B)承擔預防(PrEP)一端。肝病貢獻 $3.22B(病毒性肝炎的 Epclusa 與 Vemlidy、原發性膽汁性膽管炎的 Livdelzi)。腫瘤貢獻 $3.24B:抗體藥物偶聯物 Trodelvy($1.40B)與 Kite Pharma 的 CAR T 細胞療法 Yescarta、Tecartus(合併 $1.84B)。Veklury(瑞德西韋)隨新冠住院人數下降已回落至 $0.91B。
商業模式是嵌入臨床指引的慢性療法、極高的毛利率(FY2025 為 78.8%),轉化為研發資金——$5.80B 研發支出與 50 多個臨床階段項目——以及紀律性的外部科學收購(2011 年 Pharmasset、2017 年 Kite、2020 年 Immunomedics、2024 年 CymaBay)。當前增長故事是 lenacapavir:首創的衣殼抑制劑、每半年給藥一次,治療端是 Sunlenca,預防端是 2025 年 6 月獲批、首個每半年一次的 PrEP 方案 Yeztugo。
業務板塊 — FY2025 按產品領域劃分的收入
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| HIV | $20.75B | 70.5% | +6% |
| 腫瘤 | $3.24B | 11.0% | −2% |
| 肝病 | $3.22B | 10.9% | +6% |
| Veklury(新冠) | $0.91B | 3.1% | −49% |
| 其他產品 | $0.80B | 2.7% | −10% |
| 授權、合約及其他 | $0.53B | 1.8% | +266% |
| 總收入 | $29.44B | 100% | +2% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1987 | 由醫師 Michael L. Riordan 在加州福斯特城創立 |
| 1992 | 於 NASDAQ 上市 |
| 2001 | Viread(tenofovir)獲批,HIV 產品線開始成形 |
| 2006 | Atripla——首個每日一次的 HIV 單片方案(與必治妥施貴寶合作) |
| 2011 | 宣布以 $11B 收購擁有 sofosbuvir 的 Pharmasset |
| 2013 | Sovaldi 上市,可治癒的 C 型肝炎時代開啟 |
| 2014 | Harvoni——首個全口服、無干擾素的 HCV 治癒方案 |
| 2016 | Epclusa——首個泛基因型 HCV 方案 |
| 2017 | 以 $11.9B 收購 Kite Pharma;Yescarta 成為首創 CAR T 細胞療法 |
| 2018 | Biktarvy 上市並成長為全球領先的 HIV 方案 |
| 2019 | Daniel O’Day 出任董事長兼執行長 |
| 2020 | Veklury(瑞德西韋)成為首個獲 FDA 批准的新冠治療;以 $21B 收購 Immunomedics(Trodelvy) |
| 2022 | Sunlenca(lenacapavir)獲批——首個每半年一次的 HIV 治療選項 |
| 2024 | 收購 CymaBay Therapeutics,納入 Livdelzi(原發性膽汁性膽管炎) |
| 2025 | Yeztugo(lenacapavir)獲批為每半年一次的 HIV 預防(PrEP)方案 |
競爭地位
財務快照 — FY2025
| 總收入 | $29.44B(同比 +2%) |
| 產品銷售 | $28.92B · 佔總收入 98.2% |
| 毛利 | $23.21B · 毛利率 78.8% |
| 營業利潤 | $10.02B · 利潤率 34.0% |
| 淨利潤 | $8.51B · 淨利率 28.9% |
| 稀釋 EPS | $6.78(FY2024 為 $0.38,見註) |
| 經營現金流 | $10.02B |
| 現金與可出售債務證券 | $10.61B(2025年12月31日) |
| 研發支出 | $5.80B · 佔收入 19.7% |
主要風險
對標普500的重要性
吉利德是標普500 第 #58 大成分股、權重 0.29%,在醫療健康板塊內排 #8——GILD 波動 1% 只直接推動指數約 0.3 個基點,但它是市場上最純粹的大型 HIV 曝險、又是醫療健康前十名成分,其業績對生物科技情緒的引導遠超自身權重(XLV 與 XBI 都會跟動)。
對指數與 0DTE 交易者:吉利德在 2 月、5 月、8 月、11 月的生物科技財報窗口發報,lenacapavir 的監管與臨床消息會無預警落地,華盛頓的 HIV 政策新聞能讓整個抗病毒族群跳空——GILD 通常是這類資金流最先表達的 tick。
來源與方法
| 財務、產品銷售、員工 | 吉利德 FY2025 Form 10-K(2026年2月24日申報;會計年度截至2025年12月31日) |
| 指數權重與排名 | Slickcharts 標普500權重,2026年10月29日抓取(凍結基準) |
| 市值與板塊排名 | StockAnalysis 標普500清單,2026年10月28日收盤快照;GICS 板塊據 S&P 500 公司清單(Wikipedia) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 圖表 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-29 10:44 · updated 2026-11-14 23:27 · rev 6